Chronic Idiopathic Constipation Market to Reach USD 11.3 Billion by 2035, Impelled by Heightened Rate of Risk Factors Contributing to Chronic Idiopathic Constipation

March 19, 2025 | Healthcare

VIEW FULL TABLE OF CONTENTS

Chronic Idiopathic Constipation Market Outlook 2025-2035:

The 7 major chronic idiopathic constipation market reached a value of USD 6.6 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 11.3 Billion by 2035, exhibiting a growth rate (CAGR) of 5.01% during 2025-2035.

Chronic Idiopathic Constipation Market Outlook

To get more information on this market, Request Sample

The market for chronic idiopathic constipation (CIC) is growing due to the rising prevalence of the condition, which stems from an aging population, sedentary lifestyles, and suboptimal dietary habits. In line with this, the advancement of innovative drugs and alternative treatments has captured the interest of patients and healthcare provider interests because of the availability of novel treatment options. The increased understanding of CIC's everyday life effects along with growing need for treatment solutions has driven up market demand. Moreover, market expansion is supported by both improved diagnostic technologies and growing expenditure in healthcare. The treatability of bowel disorders through prescription as well as over-the-counter treatments enhances accessibility, while the ongoing digestive health interest guarantees the CIC market's expansion.

Heightened Rate of Risk Factors Contributing to Chronic Idiopathic Constipation: Driving the Chronic Idiopathic Constipation Market

As our understanding of the condition grows, the demand for specialized treatments and diagnostic tools is also rising, driving the shift towards precision medicine. With the increase in lifestyle-related risk factors and the rising demand for better treatment options, the CIC market is expected to continue expanding in the future.

Chronic idiopathic constipation (CIC) market growth occurs due to maintaining factors associated with its increasing prevalence across populations. An aging population combined with sedentary life choices, unhealthy diet, and increasing stress levels drives the higher incidence of gastrointestinal problems leading to CIC. Older adults face a higher risk of chronic constipation due to age-related changes in digestion and the impact of medications, which often exacerbate bowel movement challenges. Moreover, the increasing understanding of CIC drives greater patient need for effective treatment methods, thereby favoring the market growth. In confluence with this, the growing importance of alternative medical treatments, including anti-diarrheal drugs and medications, which affect both guanylate cyclase-C agonists and serotonin receptors, persists along with traditional intervention methods like physical exercise advising and nutritional adjustments. Additionally, the development of innovative therapies targeting the microbiome and bio-based solutions is opening up new opportunities for the market. Improvements in healthcare access, particularly in emerging markets, are making it easier for more people to seek treatment for CIC, furthering market expansion.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The treatment options for chronic idiopathic constipation (CIC) are rapidly evolving, driven by the development of innovative therapies. Research has shown that traditional treatments consisting of fiber supplements and laxatives frequently fail at treating symptoms persistently, which generates substantial market need for new effective treatments. The pharmaceutical industry made substantial progress by developing medication which addresses CIC's fundamental causes including slow gut motility together with decreased fluid secretion and misbalanced gut microbiome. New medication categories with prokinetic agents, secretagogues, and neuromodulators are emerging to address varying aspects of the condition. Moreover, plecanatide and other new drugs act in the gut by enhancing chloride secretion which results in improved bowel movements and decreased abdominal distress. Other treatments, like target serotonin receptors to enhance gut motility, offering options for patients who don’t respond to conventional therapies. The market for CIC treatments is escalating as more medical professionals recognize the condition as a chronic issue that requires ongoing management. Pharmaceutical companies are investing heavily in the development of new drugs that offer fewer side effects and better adherence, which is helping to grow the market. Regulatory approvals for new therapies, as well as advancements in diagnostic techniques, are making treatments more accessible to patients. In addition to oral medications, injectable and biologic therapies are also being explored, offering more treatment options. As awareness of CIC increases and new treatments become available, the demand for effective solutions is expected to grow, driving further market expansion.

Marketed Therapies in Chronic Idiopathic Constipation Market

Linzess (Linaclotide): AbbVie/Ironwood Pharmaceuticals

Linzess (Linaclotide), developed by Ironwood Pharmaceuticals and AbbVie, is an oral medication approved for the treatment of chronic idiopathic constipation (CIC) in adults. It works as a guanylate cyclase-C agonist, increasing fluid secretion and accelerating bowel movements while reducing abdominal discomfort.

Motegrity (Prucalopride): Takeda

Motegrity (Prucalopride), developed by Takeda, is an oral medication approved for the treatment of chronic idiopathic constipation (CIC) in adults. It is a selective serotonin-4 (5-HT4) receptor agonist that enhances colonic motility, promoting bowel movements and alleviating constipation symptoms. With a well-established safety profile, it is designed to improve overall bowel function and reduce the discomfort associated with CIC.

Trulance (Plecanatide): Bausch Health Companies

Trulance (Plecanatide), developed by Bausch Health Companies, is an oral medication approved for the treatment of chronic idiopathic constipation (CIC) in adults. It functions as a uroguanylin analog, activating guanylate cyclase-C receptors in the gastrointestinal tract to increase fluid secretion and support regular bowel movements. Trulance is designed to provide effective relief from constipation while minimizing side effects such as diarrhea.

Amitiza (Lubiprostone): Mallinckrodt

Amitiza (Lubiprostone), developed by Mallinckrodt, is an oral medication approved for the treatment of chronic idiopathic constipation (CIC) in adults. It works by activating chloride channels in the intestinal lining, increasing fluid secretion to soften stool and promote regular bowel movements. Amitiza also helps alleviate associated symptoms such as bloating and abdominal discomfort, offering a well-tolerated treatment option for CIC.

Drug Name	Company Name	MOA	ROA
Linzess (Linaclotide)	AbbVie/Ironwood Pharmaceuticals	Enterotoxin receptor agonists	Oral
Motegrity (Prucalopride)	Takeda	Serotonin 4 receptor agonists	Oral
Trulance (Plecanatide)	Bausch Health Companies	Enterotoxin receptor agonists	Oral
Amitiza (Lubiprostone)	Mallinckrodt	Chloride channel agonists	Oral

Detailed list of marketed and emerging therapies in Chronic Idiopathic Constipation is provided in the final report…

Leading Companies in the Chronic Idiopathic Constipation Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global chronic idiopathic constipation market, several leading companies are at the forefront of developing integrated platforms to enhance the management of chronic idiopathic constipation. Some of the major players include Bausch Health Companies, Mallinckrodt, Takeda, AbbVie, and others. These companies are driving innovation in the chronic idiopathic constipation market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for chronic idiopathic constipation.

In early January 2025, ANI Pharmaceuticals announced the FDA approval and launch of Prucalopride Tablets, granted a 180-day Competitive Generic Therapy (CGT) exclusivity. Prucalopride is a selective serotonin-4 (5-HT4) receptor agonist that enhances colonic motility, offering a treatment option for adults with chronic idiopathic constipation.

Key Players in Chronic Idiopathic Constipation Market:

The key players in the chronic idiopathic constipation market who are in different phases of developing different therapies are Ironwood Pharmaceuticals, Takeda, ANI Pharmaceuticals, Sebela Pharmaceuticals, Bausch Health Companies, Mallinckrodt, AbbVie, and Others.

Key Players in Chronic Idiopathic Constipation Market

Regional Analysis:

The major markets for chronic idiopathic constipation include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for chronic idiopathic constipation while also representing the biggest market for its treatment. Recent advancements in the treatment of chronic idiopathic constipation (CIC) include the development of new pharmacological agents such as plecanatide which improve bowel movements by targeting intestinal secretory pathways. Innovations like peripherally acting mu-opioid receptor antagonists address opioid-induced constipation. Digital health tools, such as biofeedback therapy and personalized apps, are enhancing patient self-management. Additionally, dietary and microbiome-based interventions, including prebiotics and probiotics, are gaining traction as complementary approaches. These advancements aim to improve symptom relief and quality of life for CIC patients.

Recent Developments in Chronic Idiopathic Constipation Market:

In May 2023, the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) released new guidelines for the pharmacological treatment of chronic idiopathic constipation (CIC) in adults. These guidelines are the first to recommend Magnesium Oxide and Senna as evidence-based treatment options. This joint clinical practice guideline, published today in the scientific journals of both societies, marks a significant step in advancing the management of chronic constipation.

Key information covered in the report

Base Year: 2024
Historical Period: 2019-2024
Market Forecast: 2025-2035

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic idiopathic constipation market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic idiopathic constipation market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current chronic idiopathic constipation marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact Us:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Chronic Idiopathic Constipation Market to Reach USD 11.3 Billion by 2035, Impelled by Heightened Rate of Risk Factors Contributing to Chronic Idiopathic Constipation

Purchase Options Discount
Offer

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.